Minireviews

Mitochondrial-Based Therapeutics for the Treatment of Spinal Cord Injury: Mitochondrial Biogenesis as a Potential Pharmacological Target

Natalie E. Scholpa and Rick G. Schnellmann

Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona (N.E.S., R.G.S.); and Southern Arizona VA Health Care System, Tucson, Arizona (R.G.S.)

Received August 28, 2017; accepted September 20, 2017

ABSTRACT

Spinal cord injury (SCI) is characterized by an initial trauma followed by a progressive cascade of damage referred to as secondary injury. A hallmark of secondary injury is vascular disruption leading to vasoconstriction and decreased oxygen delivery, which directly reduces the ability of mitochondria to maintain homeostasis and leads to loss of ATP-dependent cellular functions, calcium overload, excitotoxicity, and oxidative stress, further exacerbating injury. Restoration of mitochondrial dysfunction during the acute phases of secondary injury after SCI represents a potentially effective therapeutic strategy. This review discusses the past and present pharmacological options for the treatment of SCI as well as current research on mitochondria-targeted approaches. Increased antioxidant activity, inhibition of the mitochondrial permeability transition, alternate energy sources, and manipulation of mitochondrial morphology are among the strategies under investigation. Unfortunately, many of these tactics address single aspects of mitochondrial dysfunction, ultimately proving largely ineffective. Therefore, this review also examines the unexplored therapeutic efficacy of pharmacological enhancement of mitochondrial biogenesis, which has the potential to more comprehensively improve mitochondrial function after SCI.

Introduction

There are over 12,000 new cases of spinal cord injury (SCI) in the United States every year, and although active individuals at any age can fall victim, the majority of injuries take place in males younger than age 30 years (Devivo, 2012). The consequences of spinal cord trauma can range from loss of function to complete paralysis below the injury site. The lack of therapeutics capable of restoring function results in this patient population being dependent on healthcare support for the remainder of their lifetime. Nevertheless, with advancements in medical and surgical care, survivors of SCI generally live long lives after injury, with life expectancy correlating with SCI-induced neurologic impairment (Wyndaele and Wyndaele, 2006; Middleton et al., 2012).

Unfortunately, patients with SCI often develop progressive complications in addition to their injury, including cardiovascular disease, gastrointestinal problems, chronic pain, and depression (Myers et al., 2007). The resulting cost of care is estimated at greater than $3 million per patient (Devivo, 2012), which places a tremendous burden on patients, caregivers, and the healthcare system in general and demonstrates the need for continued research on the development of therapeutics for individuals suffering from SCI. Furthermore, the development of more effective ways of maintaining and recovering function after SCI could allow patients greater levels of both independence and productivity, drastically improving patient outlook.

SCI Pathology

SCI occurs in two phases: primary injury and secondary injury (Fig. 1). Primary injury refers to the immediate mechanical trauma to the spinal cord, which can be caused by compression, contusion, or distension; the most common of

ABBREVIATIONS: ALC, acetyl-L-carnitine; CNS, central nervous system; CsA, cyclosporin A; ETC, electron transport chain; GSH, glutathione; LP, lipid peroxidation; MB, mitochondrial biogenesis; MP, methylprednisolone; mPTP, mitochondrial permeability transition pore; NACA, N-acetylcysteinamide; NASCIS, National Acute Spinal Cord Injury Study; NIM811, N-methyl-4-isoleucine cyclosporin; PDH, pyruvate dehydrogenase; PGC, peroxisomal proliferator γ coactivator; ROS, reactive oxygen species; SCI, spinal cord injury; TBI, traumatic brain injury; TFAM, mitochondrial transcription factor A.
these is contusion (Sekhon and Fehlings, 2001; Baptiste and Fehlings, 2006). Complete spinal cord transection can occur but little to no functional recovery has been observed with pharmacological intervention alone in these instances; however, combinatorial therapies involving cellular transplantation have shown some promise (Coumans et al., 2001; Fouad et al., 2005). There exists the possibility for pharmacological intervention to aid in recovery after incomplete spinal cord transection, such as that generally observed after contusion, because the remaining intact tissue has the potential for repair (Hall and Springer, 2004). For the purposes of this review, we focus on incomplete transection.

Within the first minutes to hours after injury, a secondary cascade is initiated, which can last for weeks or months and whose damaging effects are comparative to, if not greater than, that of the initial insult (Tanhoffer et al., 2007; Oyinbo, 2011). Consequences of secondary injury include progressive axon demyelination (Totoiu and Keirstead, 2005), neuronal cell death (Beattie et al., 2002; Anwar et al., 2016), microglia activation and inflammation (Qiao et al., 2010, 2015), glial scar formation (Shibuya et al., 2009), and mitochondrial dysfunction, all of which contribute to the progressive pathology. Because of the far-reaching effects of secondary injury, pharmacological therapeutics that seek to interrupt or control this stage of injury have the potential to improve neuron survival, allowing functional recovery (Hall and Sullivan, 2005; Oyinbo, 2011).

Over 25 mechanisms of secondary injury after SCI—as well as a temporal association of their occurrences, ranging from seconds (acute) to years (chronic) postinjury—have been identified (Oyinbo, 2011). For a more thorough discussion of secondary injury, see reviews by Tator and Fehlings (1991), Anderson and Hall (1993), Hall and Springer (2004), and Rowland et al. (2008). In brief, the initial primary trauma results in mechanical disruption of the spinal cord vasculature, leading to vasoconstriction and contributing to hemorrhage, edema, hypoperfusion, and ischemia (Baptiste and Fehlings, 2006; Graumann et al., 2011). Ischemia is considered a key mechanism of secondary injury, with the degree of functional loss being proportional to the degree of ischemia postinjury (Tator and Fehlings, 1991). Although angiogenesis does take place after SCI, the emerging vessels are often leaky and therefore do not allow for the necessary delivery of nutrients or removal of waste within the injured spinal cord (Kundi et al., 2013). Furthermore, the subsequent local decrease in oxygen delivery directly reduces the ability of mitochondria to maintain homeostatic function (Graumann et al., 2011; Kundi et al., 2013).

**Mitochondria after SCI.** Mitochondria are double-membraned organelles that, through oxidative phosphorylation, produce the majority of ATP for the cell. The outer mitochondrial membrane is a phospholipid bilayer containing voltage-dependent anion channels that, when open, allow the passage of small molecules, including ions, ATP, and ADP (Lemasters and Holmuhamedov, 2006; McEwen et al., 2011). The more complex inner membrane, while freely permeable to oxygen, water, and carbon dioxide, contains numerous tightly controlled channels, which regulate the electron transport chain (ETC) to maintain the necessary electrochemical gradient ($\Delta \psi$) for ATP synthesis (Saraste, 1999; Kinnally et al., 2011). Various reactive oxygen species (ROS) (e.g., superoxide anion, hydrogen peroxide, and hydroxyl radicals) can be formed when electrons leak from the ETC and combine with $O_2$ in the mitochondrial matrix. Under control circumstances, endogenous antioxidant systems protect from ROS-induced toxicity (Candas and Li, 2014); however, disruption of the ETC under pathologic conditions can cause not only an energy deficit due to loss of ATP synthesis but also an increase in ROS production (Turrens, 2003) beyond the neutralizing capabilities of antioxidant systems.

Recently, understanding of the role of mitochondria within the central nervous system (CNS) has shifted from merely energy suppliers to essential contributors to both neural homeostasis and neurodegeneration (Dubinsky, 2005). Mitochondrial dysfunction after SCI has been suggested to be crucial for the proliferation of secondary injury and subsequent neuronal cell death (Sullivan et al., 2007). Neurons depend on stringent and efficient ATP-dependent regulation.
of various ions across the plasma membrane to maintain electrical homeostasis and to readily accommodate action potential conduction and the release/uptake of neurotransmitters. In addition, neurons have limited capacity to buffer oxidative stress (Adibhatla and Hatcher, 2010).

Given these large energy requirements and limited antioxidant defenses, neurons rely heavily on mitochondrial metabolism and ATP production and are susceptible to compromised mitochondria (Uttara et al., 2009; Moskowitz et al., 2010; Wang and Michaelis, 2010); even small mitochondrial defects can cause functional consequences and eventual pathology within the CNS (Dubinsky, 2005). Loss of mitochondrial function, such as that observed with secondary injury after SCI, results in the loss of ATP and inactivation of ATP-dependent ion pumps required for regulation of ion concentrations as well as reuptake of the excitatory neurotransmitter glutamate. This dysfunction ultimately leads to excitotoxicity, calcium overload, and the eventual initiation of cell death cascade, all of which are hallmarks of SCI and further exacerbate injury in this self-propagating cycle (Choi and Rothman, 1990; Rowland et al., 2008; Oyinbo, 2011).

An early secondary event after SCI is depolarization and opening of voltage-dependent ion channels, leading to the release of neurotransmitters, including glutamate. Glutamate binds to glutamate receptors, opens corresponding ion channels, and results in accumulation of intracellular Ca$^{2+}$ (Hall and Springer, 2004). Such ionic shifts can persist for days in injured tissue after SCI (Young and Koreh, 1986; Demediuk et al., 1990; LoPachin et al., 1999). Under control conditions, mitochondria can sequester and retain exogenous Ca$^{2+}$ via an electrogenic carrier that facilitates transport across the inner membrane. Once Ca$^{2+}$ is in the mitochondrial matrix, Ca$^{2+}$ is stored in the form of inactive precipitates, which are eventually slowly released back into the cytosol (Crompton, 1999; Starkov, 2010). When Ca$^{2+}$ is accumulated above a certain threshold, however, Ca$^{2+}$ will trigger the opening of the mitochondrial permeability transition pore (mPTP; Fig. 2).

The opening of the mPTP results in the loss of $\Delta \psi$ leading to the cessation of ATP synthesis and has been linked to necrosis and apoptosis after brain injury, neurodegenerative disorders, and SCI (Hirsch et al., 1998; Lemasters et al., 1998; Crompton, 1999; Friberg and Wieloch, 2002; Norenberg and Rao, 2007; Bezprozvanny, 2009; Pivovarova and Andrews, 2010). In addition, opening of the pore allows molecules and water into the mitochondria, causing the matrix to swell as it equilibrates with the cytosol and enlarging the inner membrane until the outer membrane ruptures, releasing accumulated Ca$^{2+}$, ROS, and proapoptotic proteins (e.g., cytochrome c) into the cytosol, and promoting cell death (Sesso et al., 2004; McEwen et al., 2011). Importantly, Sullivan et al. (2004a) demonstrated that spinal cord mitochondria have a reduced Ca$^{2+}$ threshold for opening of the mPTP than that of mitochondria isolated from the brain, further indicating the necessity of restoring mitochondrial homeostasis after SCI.

A consequence of the persistent ion shift during secondary injury is increased ROS. ROS are normal byproducts of mitochondrial function, but Ca$^{2+}$ overload increases production in the CNS (Lewén and Hillered, 1998; Sullivan et al., 2004b). SCI induces a detrimental self-propagating cycle of increased ROS production, leading to oxidative damage and...
additional ROS production, until pathologic levels are eventually reached. A particularly detrimental consequence of ROS is the formation of the powerful oxidant peroxynitrite (Violi et al., 1999). Development of peroxynitrite is increased after injury due to the increased concentration of superoxide and Ca\(^{2+}\)-induced activation of nitric oxide synthase within the mitochondria (Bringold et al., 2000). Peroxynitrite can also trigger cell membrane lipid peroxidation (LP), protein carbonylation, and tyrosine nitration, damaging and impairing mitochondria and altering neuronal function after SCI (Violi et al., 1999; Sullivan et al., 2007; Hall et al., 2016).

LP results in additional free radicals, which propagate damage (Hall et al., 2016). LP can occur in blood vessels and neurons, which not only impairs neuronal and vascular integrity but also promotes ischemia and further contributes to secondary neuronal injury (Hall and Springer, 2004). Targeting reestablishment of mitochondrial homeostasis prior to damaging levels of ROS formation could potentially attenuate secondary injury after SCI. Temporal analysis revealed altered mitochondrial morphology beginning 2 hours after SCI, with increases in markers of oxidative damage beginning approximately 8 hours after injury and continuing until at least 24 hours after SCI (Sullivan et al., 2007; Jia et al., 2016). These data reveal the potential existence of an 8-hour window for therapeutic intervention to regain mitochondrial homeostasis after SCI.

**Current Treatment of SCI: The National Acute Spinal Cord Injury Study and Methylprednisolone**

Based on their ability to reduce peritumoral brain edema in patients with tumors, glucocorticoid steroids, including methylprednisolone (MP), were primarily used to treat SCI in 1960s and 1970s, with the assumption that they would also reduce post-SCI edema (Reulen et al., 1973). The first National Acute Spinal Cord Injury Study (NASCIS I), a clinical trial performed in the early 1980s, showed that the benefits of steroid treatment were limited, if not nonexistent. Furthermore, increased risk of infection, a known side effect of glucocorticoids, was observed with high-dose treatments (Bracken et al., 1984, 1985). Based on these findings, a general consensus within the neuroscience community was reached, which concluded that the use of steroids after SCI was simultaneously risky and unhelpful (Hall and Springer, 2004).

NASCIS II took place in the 1990s following enhanced understanding of the mechanism of post-SCI LP (Hall and Braugher, 1981; Anderson et al., 1982; Young and Flamm, 1982; Hall et al., 1984). The findings from this study revealed that patients functionally benefited from treatment with high-dose MP (30 mg/kg i.v. bolus plus hourly 5.4 mg/kg for 23 hours), presumably via LP inhibition resulting in decreased injury progression, as long as dosing was initiated within 8 hours postinjury (Bracken et al., 1990, 1992; Bracken and Holford, 1993). Based on these data, the standard of care for the treatment of SCI became the systemic administration of MP for 24 hours (Rabchevsky et al., 2011). In the late 1990s, the NASCIS III clinical trial evaluated MP using the same dosing regimen used in NASCIS II, extended MP doses (48 hours), and a third treatment consisting of one 30-mg/kg MP bolus followed by 48-hour administration of tirilazad, a nonglucocorticoid steroid (Braugher et al., 1988; Hall et al., 1994; Bracken et al., 1997, 1998). In general, all three treatment groups produced comparable degrees of recovery when initiated within 3 hours after SCI. When initiated between 3 and 8 hours postinjury, 48-hour MP was the most effective but also had the highest incidence of glucocorticoid-related side effects (Bracken et al., 1997, 1998).

There are many potential side effects of high doses of MP, including an increased risk of gastrointestinal bleeding, deep vein thrombosis, pneumonia, septic shock, and delayed wound healing (Evaniew et al., 2015), which can offset the neuroprotective effects of MP and compromise functional outcome and even survival. In addition, treatment initiation past the 8-hour window can actually exacerbate injury and decrease recovery compared with no treatment (Bracken and Holford, 1993). Glucocorticoid-induced neurotoxicity has also been observed in certain neuronal populations, such as the hippocampus (Sapolsky, 1985; McIntosh and Sapolsky, 1996).

In the decade after the NASCIS trials, multiple highly critical reviews of the studies surfaced, which criticized the lack of functional assessment, the lack of placebo groups, the safety of high-dose MP, and the small effect sizes in only a subpopulation of patients (Coleman et al., 2000; Huribert, 2000; Short et al., 2000; Evaniew et al., 2015). In 2013, the Guidelines for the Management of Acute Cervical Spine and Spinal Cord Injuries were updated, downgrading data obtained from the NASCIS trials from class I (“well executed”) to class III (“unhelpful for establishing quality”) and they no longer recommend the use of MP for the treatment of acute SCI, stating that the evidence supporting beneficial effects was inconsistent and likely due to random chance (Walters et al., 2013). As such, treatment with MP after SCI is now up to the discretion of the attending physician (Rabchevsky et al., 2011).

**Mitochondrial-Based Treatment**

Despite promising treatments in animal models of SCI, there is currently no meaningful therapy for the treatment of SCI in humans. Secondary injury is a complex cascade of events that initiates many additional pathologies; therefore, therapeutics targeting specific downstream events after SCI may prove merely palliative and ultimately nonneflicacious. Based on temporal data presented by Sullivan et al. (2007), restoration of mitochondrial function shortly after injury may be a more comprehensive approach for the treatment of SCI (McEwen et al., 2011; Rabchevsky et al., 2011).

Many pharmacological agents that have proven beneficial for the treatment of SCI in vivo affect mitochondria or mitochondrial function to some extent. For example, the antibiotic minocycline was found to have neuroprotective effects and induce behavioral and cellular recovery after SCI in rats (Wells et al., 2003; Teng et al., 2004; Sonmez et al., 2013; Aras et al., 2015; Ahmad et al., 2016). The spectrum of effects of minocycline includes mitochondrial stabilization, inhibition of the release of cytochrome c, and antioxidant activity (Wells et al., 2003; Casha et al., 2012; Aras et al., 2015). In addition, lithium treatment has been reported to stimulate mitochondrial respiration in human brain tissue and to enhance neuronal regeneration after SCI in vivo (Yick et al., 2004; Maurer et al., 2009). Unfortunately, however, both of these treatments proved ineffective during phase II clinical trials (Casha et al., 2012; Yang et al., 2012). Restoration of mitochondrial function after SCI remains a popular therapeutic strategy and can be targeted directly via several
different mechanisms, including inhibition of the mPTP, the use of alternate energy sources, enhanced antioxidant activity, and altered mitochondrial morphology.

**Inhibition of the mPTP.** As stated previously, opening of the mPTP contributes to several pathologic events that take place during secondary injury. Therefore, targeting components of the mPTP to inhibit the mitochondrial permeability transition after SCI may have therapeutic benefits (Fig. 2). The immunosuppressant cyclosporin A (CsA) binds to and inhibits the mPTP and has been associated with enhanced mitochondrial function and decreased cell death in the CNS (Waldmeier et al., 2003; Basso et al., 2005; Kim et al., 2014). Particularly, studies have demonstrated that CsA has neuroprotective properties in models of traumatic brain injury (TBI) and stroke (Matsumoto et al., 1999; Scheff and Sullivan, 1999; Sullivan et al., 1999, 2000; Uchino et al., 2002).

Unfortunately, assessments of the neuroprotective effects of CsA after SCI have proven inconclusive and inconsistent (Ibarra et al., 1996a,b, 2003; Rabchevsky et al., 2001; McMahon et al., 2009). Differences in the efficacy of CsA between TBI and SCI may be attributed to fundamental differences in spinal cord and cortical mitochondria (Sullivan et al., 2004a). Regardless of any positive results, however, CsA is highly toxic, making it less than ideal as a therapeutic (Caramelo et al., 2004; Schenk et al., 2010; Rabchevsky et al., 2011; Szalowska et al., 2015). NIM811 (N-methyl-4-isoeucine cyclosporin) is an analog of CsA that also inhibits the mPTP, is much less toxic, and lacks immunosuppressive properties (Waldmeier et al., 2002). Very few studies have been performed regarding the therapeutic potential of NIM811 in the CNS, with even fewer investigating SCI (Waldmeier et al., 2002; McEwen et al., 2007; Ravikumar et al., 2007; Mbye et al., 2008, 2009). The data obtained from these limited studies, however, suggest that NIM811 induces neuroprotection after SCI (McEwen et al., 2007; Ravikumar et al., 2007) and strongly indicate that the therapeutic efficacy of NIM811 deserves further investigation.

**Alternate Energy Sources: “Biofuels.”** After SCI, several mitochondrial enzymes are inactivated due to oxidative damage. One such example is pyruvate dehydrogenase (PDH), a critical enzyme in the generation of acetyl-CoA (McEwen et al., 2011). Acetyl-CoA is necessary for the citric acid cycle and the production of NADH and FADH$_2$, electron donors for the ETC. Because of this PDH deficit, introduction of alternate energy sources (“biofuels”) could potentially alleviate mitochondrial dysfunction after SCI (Fig. 2).

Acetyl-
£-carnitine (ALC) is an endogenous component of the inner mitochondrial membrane that readily crosses the blood-brain barrier and provides acetyl groups to facilitate the synthesis of acetyl-CoA, thereby bypassing the need for PDH (Pettegrew et al., 2000; McEwen et al., 2011). ALC also increases the production of glutathione (GSH), giving it a bipartite effect and further increasing its therapeutic appeal (Pettegrew et al., 2000; Karalija et al., 2012). ALC is shown to have beneficial effects for a number of neurodegenerative diseases, including Parkinson disease, Alzheimer disease, and multiple sclerosis (Puca et al., 1990; Pettegrew et al., 2000; Tomassini et al., 2004). Interestingly, Karalija et al. (2012) demonstrated that chronic ALC administration reduces neuronal degeneration after SCI in rats. Furthermore, Patel et al. (2010, 2012) found that treatment with ALC after SCI maintained mitochondrial function, improved functional recovery, and protected both white and gray matter within the spinal cord from further injury. ALC administration was also shown to reduce the number of damaged mitochondria, improve mitochondrial membrane potential, and decrease SCI-induced apoptosis in rats (Zhang et al., 2015). These studies, although few in number, suggest the potential for ALC as a therapeutic treatment of SCI.

**Antioxidant Approaches.** The consequences of ROS formation and oxidative damage after SCI are well characterized and were briefly discussed above. For a more comprehensive description, see a review by Hall (2011). For a more thorough review on antioxidant-based therapies for the treatment of SCI, see Bains and Hall (2012). Pharmacological intervention of oxidative damage after SCI (Fig. 2) can occur via several different mechanisms, both direct and indirect. Indirect mechanisms include preventing the formation of ROS and ROS scavenging; direct mechanisms include halting LP propagation or scavenging LP-induced free radicals (Hall, 2011; Bains and Hall, 2012). A short therapeutic window is one significant limitation of the aforementioned indirect mechanisms. Multiple studies have reported near instantaneous increases in ROS production after SCI (Liu et al., 1998, 2004; Bao and Liu, 2004; Xiong et al., 2007), which means that pharmacological agents would need to be administered immediately to ensure that they are able to act and interfere with the initial “burst” of free radical production that occurs after SCI (Hall, 2011; Bains and Hall, 2012; Hall et al., 2016).

α-Tocopherol is a naturally occurring form of vitamin E, which can scavenge lipid peroxyl radicals and has been shown to improve recovery and decrease LP after SCI (Anderson et al., 1988; Bozbuga et al., 1998; Al Jadid et al., 2009; Morsy et al., 2010; Morsy and Bashir, 2013). Unfortunately, this process is 1:1 and the radical form of vitamin E is produced after scavenging, which has no antioxidant properties. Furthermore, it has been suggested that high-dose supplementation of vitamin E, such as that which would be necessary to decrease baseline LP levels in humans (Roberts et al., 2007), can increase mortality (Miller et al., 2005) and thus should be avoided.

N-acetylcysteineamide (NACA), a membrane-permeable U.S. Food and Drug Administration–approved thiol-containing variant of the GSH precursor N-acetylcysteine, was observed to enhance GSH content, improving mitochondrial bioenergetics and correlating with functional recovery in rat models of both TBI and SCI when administered 15–30 minutes postinjury (Pandya et al., 2014; Patel et al., 2014). Although these results are undoubtedly encouraging, additional studies must be performed to assess the therapeutic window for treatment initiation, particularly considering that N-acetylcysteine was previously shown to be ineffective in rats if not given within 1 hour after TBI (Xiong et al., 1999).

Spin trap molecules, such as the free radical scavengers tempol (4-hydroxy-2,2,6,6-tetramethylperipiperidine-N-oxyl) and Neu2000 (2-hydroxy-5-[2,3,5,6-tetrafluoro-4-trifluoro-methylbenzylamino]-benzoic acid), have produced inconsistent results after SCI, in part due to their lack of targeted mitochondrial selectivity (Patel et al., 2009; Xiong et al., 2009; Springer et al., 2010; McEwen et al., 2011; Visavadhy et al., 2013). Biomolecules consisting of antioxidants covalently bonded to mitochondrial targeting compounds (e.g., triphenylphosphonium cation) have been generated to combat this limitation (Murphy, 1997, 2001; Murphy and Smith,
cytochrome injury, mitochondrial membrane potential decreased, and spinal cord Drp1 increased within the first 24 hours after effect of the trauma (Liu et al., 1997). It was observed that as abundantly due to apoptosis after injury, as opposed to a direct addition, studies have indicated that spinal cord cell death is only morphology but also cellular function and apoptosis, in

Mitochondria change form and function to meet requirements of the cell; as such, they are both highly controlled and dynamic. Alterations in the size and number of mitochondria are regulated by the coordination of fission (the division of single mitochondria into multiple daughter mitochondria) and fusion (the formation of a single mitochondrion from previously independent structures) (Scott and Youle, 2010). In physiologic conditions, mitochondria are constantly undergoing balanced fission and fusion. Because mitochondria cannot be formed de novo, fission is necessary for cell division; however, fission and fusion are also consistently observed in many nondividing cells, partially due to the necessity of replacing or removing damaged mitochondrial components. Furthermore, mutations in fission and fusion regulatory genes are associated with various pathologies, indicating the importance of normal mitochondrial dynamics (Züchner et al., 2004; Ranieri et al., 2012).

Recently, it was shown that SCI alters fission and fusion, contributing to mitochondrial dysfunction. Cao et al. (2013) observed a biphasic response in mitochondrial morphology within the first 24 hours after SCI in rats. At 3–6 hours after SCI, spinal cord neuronal mitochondrial were larger and fewer in number, correlating with increased expression of fusion proteins mitofusin Mfn1 and Mfn2 and decreased expression of the primary mammalian fission-related proteins mitochondrial fission 1 and dynamin-related protein 1 (Drp1). By 12–24 hours after injury, however, the opposite pattern was observed. Jia et al. (2016) performed a temporal analysis of mitochondrial morphology after SCI, which similarly revealed larger mitochondria and increased Mfn1 expression at early time points that peaked by 8 hours after SCI and then decreased by 24 hours, whereas Drp1 expression was diminished as early as 2 hours after injury and then gradually increased by 24 hours.

Mitochondrial fission and fusion are closely related to not only morphology but also cellular function and apoptosis, in that mitochondrial fission is thought to inhibit apoptosis, whereas fission is thought to promote it (Jia et al., 2016). In addition, studies have indicated that spinal cord cell death is abundantly due to apoptosis after injury, as opposed to a direct effect of the trauma (Liu et al., 1997). It was observed that as spinal cord Drp1 increased within the first 24 hours after injury, mitochondrial membrane potential decreased, and cytochrome c release and caspase-3 expression increased, culminating in apoptosis (Jia et al., 2016). These data indicate that fusion and fission are integral to early and late stages of acute SCI, respectively (Cao et al., 2013; Jia et al., 2016), and suggest that therapeutic intervention targeting fusion/fission prior to this switch could prove beneficial after SCI.

Mitochondrial division inhibitor-1 (Mdivi-1; Fig. 2), a selective Drp1 inhibitor, has proven beneficial in in vivo models of various CNS and non-CNS pathologies, including TBI (Wu et al., 2016), amyotrophic lateral sclerosis (Luo et al., 2013), stroke (Zhang et al., 2013; Cui et al., 2016), acute kidney injury (Tang et al., 2013), and myocardial infarction (Ding et al., 2017). Despite these data, only two studies thus far have investigated the effect of Mdivi-1 on SCI (Li et al., 2015; Liu et al., 2015). Li et al. (2015) observed that treatment with Mdivi-1 prior to SCI in rats increased ATP and mitochondrial membrane potential, and decreased caspase-3 release and the number of apoptotic cells by 72 hours postinjury. These effects correlated with improved locomotor function in the treated group. Similarly, Liu et al. (2015) observed neuroprotective effects of Mdivi-1, both in cultured spinal cord neurons exposed to glutamate and after ischemic/reperfusion SCI in rats. Mdivi-1 treatment resulted in increased endogenous antioxidant activity, decreased ROS, and decreased cytochrome c release in vitro, as well as improved locomotor function in vivo (Liu et al., 2015). Although these data are promising, one study used a pretreatment method, whereas the other began treatment at the initiation of injury; therefore, additional work is necessary to assess the therapeutic efficacy of Mdivi-1 after SCI.

Mitochondrial Biogenesis

The currently available therapeutics are not sufficient to effectively treat SCI. In fact, as of 2013, there was no recommended pharmacological intervention after injury (Walters et al., 2013). Although there have been promising preliminary studies investigating the efficacy of NACA, NIM811, Mdivi-1, and mitochondrial-targeted antioxidants, there remains a great deal of work to be done with these compounds and, as is often the case, there is no guarantee that the results observed in animals will translate to humans. Hall et al. (2016) suggested that combinatorial therapies could address the obvious deficit in treatment, as pursuing a single facet of the mitochondrial dysfunction-induced damage that occurs after SCI may not be enough to produce effective neuroprotection. An alternate method of targeting multiple aspects of mitochondrial function that has not yet been effectively explored for the treatment of SCI is pharmacological enhancement of mitochondrial biogenesis (MB).

Regulation of MB. MB is a transcriptional program that can be defined as the repair, growth, and/or division of preexisting mitochondria (Ventura-Clapier et al., 2008). This process involves an intricate network of several transcriptional pathways for both nuclear- and mitochondrial DNA-encoded genes, many of which are outlined in Fig. 3. MB is governed by the “master regulator” peroxisomal proliferator-activated receptor γ coactivator (PGC)-1α, which controls the expression of this network (Kelly and Scarpulla, 2004; Ventura-Clapier et al., 2008). PGC-1α interacts with and coactivates several transcription factors, including nuclear respiratory factors 1 and 2 and peroxisome proliferator–activated receptors. This results in the transcription of nuclear-encoded subunits of the ETC, including ATP synthase β and NADH:ubiquinone oxidoreductase subunit 1, antioxidant proteins such as superoxide dismutase 2, and other mitochondrial genes, including uncoupling protein 2 and mitochondrial transcription factor A (TFAM). After its transcription and translation, TFAM translocates into the mitochondrial matrix, where it stimulates mitochondrial DNA replication and the transcription of mitochondrial-encoded genes, including cytochrome c oxidase subunit 1 and NADH dehydrogenase subunit 1 (Ventura-Clapier et al., 2008). Nuclear-encoded proteins are then transferred into the mitochondria, where nuclear- and mitochondrial-encoded subunits of the ETC are assembled.

Pharmacological agents can augment MB through interaction with the various pathways that regulate this process. For example, agonism of G protein–coupled serotonin (5-hydroxytryptamine) and β-adrenergic receptors can activate the
protein kinase B/endothelial nitric oxide synthase/cGMP pathway (Wills et al., 2012; Garrett et al., 2014), enhancing MB. In addition, nitric oxide donors can stimulate cGMP activation and phosphodiesterase inhibitors can prevent the hydrolyzation of cGMP and cAMP (Cameron et al., 2016; Whitaker et al., 2016). Furthermore, resveratrol (a polyphenol that stimulates MB through activation of sirtuin 1, which catalyzes deacetylation of PGC-1α) is currently being investigated for the treatment of various neurodegenerative disorders, including Alzheimer and Huntington diseases (Kim et al., 2007; Ho et al., 2010). Although distinct, these pathways all converge on activation of PGC-1α, leading to increased MB (Fujisawa et al., 2009; Dumont et al., 2012). Fortunately, multiple pharmacological agents that induce MB are already approved by the U.S. Food and Drug Administration for the treatment of various pathologies (Table 1). Therefore, attaining approval for the use of these drugs for the treatment of SCI could be an expedient process.

**MB and SCI.** Multiple diseases and injuries, including those of the CNS, are accompanied by mitochondrial dysfunction, often including diminished MB. For example, Alzheimer, Parkinson, and Huntington diseases are all characterized by decreased PGC-1α, decreased expression of oxidative phosphorylation proteins, and, in many cases, decreased MB (Hirai et al., 2001; Chaturvedi et al., 2009; Kim et al., 2010; Coskun et al., 2012). Furthermore, ischemic injury, such as that which occurs with SCI, is also followed by reduced oxidative phosphorylation proteins as well as decreased PGC-1α and TFAM (Whitaker et al., 2016). Given this dysfunction and loss of mitochondrial proteins, interest in pharmacological enhancement of MB (and subsequently, mitochondrial gene expression) for the treatment of numerous disorders has grown. For reviews on MB for the treatment of various diseases, including pathologies of the CNS, see Whitaker et al. (2016) and Cameron et al. (2016).

Currently, no studies have investigated the effect of pharmacological activation of MB on functional recovery after SCI, although published data suggest potential therapeutic efficacy. Hu et al. (2015, 2016) recently reported that not only is PGC-1α expression decreased in the spinal cord after contusive SCI in rats, but spinal lentiviral overexpression of PGC-1α immediately after injury also attenuates neuronal cell death and promotes functional recovery, which suggests the potential benefit of pharmacologically increasing PGC-1α and MB after injury. In support of this idea, treatment of mice subjected to renal ischemia/reperfusion with mitochondrial biogenic compounds 24 hours after insult, when injury was
TABLE 1
Partial list of FDA-approved mitochondrially biogenic agents

<table>
<thead>
<tr>
<th>Drug</th>
<th>Approved to Treat</th>
<th>Mechanism</th>
<th>MB References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atorvastatin</td>
<td>SNRI</td>
<td>Add to awful</td>
<td></td>
</tr>
<tr>
<td>Cilostazol</td>
<td>PDE4 inhibitor</td>
<td>decreased blood flow</td>
<td></td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>SSRI</td>
<td>Add to awful</td>
<td></td>
</tr>
<tr>
<td>Formoterol</td>
<td>β2AR agonist</td>
<td>Add to awful</td>
<td></td>
</tr>
<tr>
<td>Metformin</td>
<td>AMPK</td>
<td>Add to awful</td>
<td></td>
</tr>
<tr>
<td>Metoprol</td>
<td>β1AR blocker</td>
<td>Add to awful</td>
<td></td>
</tr>
<tr>
<td>Rosiglitazone</td>
<td>αGc stimulator</td>
<td>Add to awful</td>
<td></td>
</tr>
<tr>
<td>Sildenafil</td>
<td>PPARy agonist</td>
<td>Add to awful</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PDE5 inhibitor</td>
<td>Add to awful</td>
<td></td>
</tr>
</tbody>
</table>

ADHD, attention-deficit/hyperactive disorder; AMPK, adenosine monophosphate-activated kinase; AR, adrenergic receptor; COPD, chronic obstructive pulmonary disease; FDA, U.S. Food and Drug Administration; MDD, major depressive disorder; OCD, obsessive-compulsive disorder; PDE, phosphodiesterase; PPAR, peroxisome proliferator-activated receptor; sGc, soluble guanylate cyclase; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.

maximal, increased PGC-1α expression and restored mitochondrial and renal function (Garrett et al., 2014; Jesinek et al., 2014a). These data indicate the need for further exploration of the therapeutic efficacy of pharmacologically augmenting MB after SCI.

Studies have also demonstrated a positive correlation between PGC-1α and angiogenesis (Arany et al., 2008; Chinsomboon et al., 2009; Saint-Geniez et al., 2013), a necessary occurrence for effective treatment of SCI pathology. Therefore, therapeutics targeting reestablishment of mitochondrial homeostasis through increased MB represent a hitherto unexploited mechanism for alleviating several facets of secondary injury progression and improving functional and vascular recovery as well as neuronal survival after SCI.

Conclusions

Targeting mitochondria for the treatment of SCI is not a novel idea. Mitochondrial dysfunction is a well-characterized consequence of secondary injury after SCI and many promising experimental therapeutics enhance mitochondrial function, although generally through prevention via pretreatment or decreased injury through early administration after insult. Unfortunately, many of these agents remain to be assessed in humans. Of the agents that have been assessed, none have yet proven successful for the treatment of SCI. A plausible explanation for this is that in general, these compounds target specific facets of mitochondrial dysfunction, which may not be enough to successfully improve patient outcome. Alternative approaches enhancing several, if not all, aspects of mitochondrial function could prove more efficacious in accelerating recovery of SCI function. Combinatorial therapies, such as pharmacologically increasing antioxidant activity and decreasing mitochondrial fission simultaneously, could address multiple aspects of mitochondrial dysfunction after SCI. Such strategies, however, would undoubtedly require a great deal of refinement and consideration of multiple factors, including drug-drug interactions. Conversely, pharmacological augmentation of MB has the potential to more efficiently address this deficit. Therefore, the efficacy of mitochondrial biogenic compounds should be investigated for the therapeutic treatment of SCI.

Authorship Contributions

Wrote or contributed to the writing of the manuscript: Scholpa, Schnellmann.

References


Downloaded from jpet.aspetjournals.org on August 13, 2022.
Mitochondrial Biogenesis for Spinal Cord Injury Treatment

Paul J. Marzinzik, Susan C. Rothman, and Kevin M. Lanting

Introduction

Mitochondria are the primary energy producers in eukaryotic cells, carrying out oxidative phosphorylation to convert oxygen and nutrients into adenosine triphosphate (ATP). They are also involved in signaling mechanisms that control cellular functions such as apoptosis, proliferation, and cellular metabolism. In the context of spinal cord injury, mitochondrial biogenesis is thought to play a critical role in preserving function and preventing neurodegeneration.

Mitochondrial Biogenesis

Mitochondrial biogenesis is the process by which the size and number of mitochondria within a cell increase. This process is regulated by transcriptional and translational mechanisms that control the synthesis of mitochondrial proteins. Mitochondrial biogenesis is typically increased in response to cellular stress, such as hypoxia, ischemia, or inflammation.

Antioxidant Therapies

Antioxidant therapies have been explored as a means to protect against the oxidative stress that occurs after spinal cord injury. These therapies include the use of vitamins, minerals, and other substances that can neutralize free radicals and prevent oxidative damage.

Glucocorticoids

Glucocorticoids are anti-inflammatory drugs that are commonly used to treat a variety of conditions. In the context of spinal cord injury, glucocorticoids have been shown to improve functional outcomes and reduce inflammation.

Glutamate Neurotoxicity

Glutamate is a excitatory neurotransmitter that is involved in many physiological processes. However, overproduction or imbalance of glutamate can lead to neurodegeneration.

Mitochondrial Dysregulation

Mitochondrial dysfunction has been implicated in the pathogenesis of many neurodegenerative diseases. Mitochondrial dysfunction can be caused by a variety of factors, including oxidative stress, inflammation, and abnormal calcium handling.

Mitochondrial Biogenesis as a Therapeutic Target

Mitochondrial biogenesis has been proposed as a potential therapeutic target for spinal cord injury. By increasing mitochondrial mass and function, therapeutic interventions aimed at enhancing mitochondrial biogenesis may provide a means to preserve or recover function after spinal cord injury.

Conclusion

Mitochondrial biogenesis is a promising therapeutic target for spinal cord injury. Further research is needed to better understand the mechanisms underlying mitochondrial biogenesis and to develop effective therapeutic interventions that can be used to treat spinal cord injury.

References


Author Information

Corresponding Author

[Author Information]
injury both in vitro and in vivo: Involvement of BK channels. *Brain Res* **1619**:31–35.
Mitochondrial Biogenesis for Spinal Cord Injury Treatment


